UPC CFI 145/2024

At the UPC: Sanofi Group (33 cases)·Accord Group (8 cases)

• 2025-09-15
  Infringement ActionPublic

  Summary: The Munich Local Division issued a post-interim-conference procedural order in consolidated infringement actions by Sanofi (and successor entities) against multiple generic companies (Accord, STADA, Dr Reddy's, Zentiva) relating to EP 2 493 466 (UPC_CFI_145–503/2024 group). The order confirmed oral hearing dates (14–17 October 2025) and directed that the four counterclaims for revocation be heard together while each infringement action is heard separately.

  Show the legal issues (3)

  • Scheduling of consolidated oral hearings
  • Joint hearing of counterclaims with separate infringement actions
  • Pharmaceutical patent — multiple generic defendants
• 2025-07-17
  Public

  Summary: Procedural order of the Munich Local Division (presiding judge Zigann) following the interim conference of 17 July 2025 in four consolidated pharmaceutical patent infringement actions by Sanofi and related entities against generics companies (Accord Healthcare, STADA, Dr. Reddy's, Zentiva) concerning EP 2 493 466. Points addressed: EPO Board of Appeal had upheld the patent but had not yet published its written reasoned decision; French parallel first-instance decisions invalidating the French designation were under appeal; defendants wished to comment on EPO BoA written reasons within three weeks of availability. No substantive infringement ruling.

  Show the legal issues (3)

  • Interaction between EPO Board of Appeal proceedings and UPC validity determination
  • French parallel invalidity decisions under appeal
  • Case management following interim conference
• 2025-07-17
  Public

  Summary: The Munich Local Division issued a scheduling order following the interim conference in the Sanofi v. Accord/STADA/Reddy/Zentiva infringement actions, setting out next procedural steps pending the written reasoning from the EPO Board of Appeal decision on the relevant patent.

  Show the legal issues (5)

  • R.105.5 RoP
  • Interim conference
  • EPO Board of Appeal decision
  • Pharmaceutical patent
  • Generics
• 2025-05-08
  Public

  Summary: The Munich Local Division judge-rapporteur issued a comprehensive interim conference order in the Sanofi pharmaceutical infringement proceedings against multiple generic manufacturers, covering the substitution of Sanofi Mature IP by Sanofi SA, interim questions of invalidity (including admissibility of counterclaims and late-filed arguments), and procedural scheduling. The order provided preliminary guidance on damages calculation methodology and noted that the EPO Board of Appeal outcome would be relevant to further steps.

  Show the legal issues (5)

  • Interim conference guidance (R. 105 RoP)
  • Validity of patent pending EPO Board of Appeal proceedings
  • Counterclaim for revocation admissibility
  • Damages calculation methodology in pharmaceutical proceedings
  • Scheduling of oral hearing
• 2025-01-22
  Public

  Summary: The Munich Local Division issued a case-management order following a preliminary interim conference in Sanofi's infringement actions (four separate cases) against multiple generic-drug defendants (Accord, STADA, Dr. Reddy's, Zentiva), setting the value of infringement claims and counterclaims, directing Sanofi to remedy formal deficiencies in its pleadings, and waiving all other outstanding deadlines pending clarification.

  Show the legal issues (4)

  • Case management following preliminary interim conference under R. 105.5 RoP
  • Formal requirements for statement of claim
  • Valuation of infringement claims and counterclaims for revocation
  • Additional court fees for infringement actions
• 2025-01-14
  Application RoP262APublic

  Summary: Procedural order from Munich Local Division dated 14 January 2025 regarding R. 262A RoP confidentiality applications filed by defendants (Accord Healthcare, Stada, Dr. Reddy's, Zentiva) in Sanofi's infringement actions concerning EP 2 493 466. The order defines which representative and company personnel on each defendant's side are permitted access to unredacted versions of confidential documents produced in the proceedings.

  Show the legal issues (2)

  • Confidentiality protection of documents under R. 262A RoP
  • Access restrictions for party representatives